PMID- 30400209
OWN - NLM
STAT- MEDLINE
DCOM- 20190611
LR  - 20200309
IS  - 2218-273X (Electronic)
IS  - 2218-273X (Linking)
VI  - 8
IP  - 4
DP  - 2018 Nov 2
TI  - Add-on Immunoadsorption Shortly-after Optimal Medical Treatment Further 
      Significantly and Persistently Improves Cardiac Function and Symptoms in 
      Recent-Onset Heart Failure-A Single Center Experience.
LID - 10.3390/biom8040133 [doi]
LID - 133
AB  - BACKGROUND: Immunoadsorption and intravenous immunoglobulin (IVIG) administration 
      may have beneficial effects in patients with dilated cardiomyopathy with 
      end-stage heart failure. We investigated the effect of immunoadsorption with 
      subsequent IVIG administration on cardiac function and symptoms in patients on 
      optimal medical treatment (OMT) for heart failure (HF) with recent-onset 
      cardiomyopathy during long-term follow-up. METHODS: Thirty-five patients with 
      recent-onset of HF symptoms received intensive guideline-recommended medical HF 
      therapy for 5.2 months. Subsequently, all patients received a single cycle of 
      immunoadsorption for five days followed by IVIG administration. During the 
      29-month follow-up period, New York Heart Association (NYHA) functional class, 
      left ventricular ejection fraction (LVEF) and N-terminal pro brain natriuretic 
      peptide (NT-proBNP) were evaluated. Changes in quality of life (QoL) were 
      assessed using the Minnesota Living with HF Questionnaire. RESULTS: Three months 
      after immunoadsorption, NYHA functional class improved from 2.0 to 1.5 (p < 
      0.005) and LVEF significantly increased from 27.0% to 39.0% (p < 0.0001). 
      Long-term follow-up of 29 months showed stable NYHA functional class and a 
      further moderate increase in LVEF from 39.0% to 42.0% (p < 0.0001) accompanied by 
      a significant improvement in NT-proBNP and QoL scores. CONCLUSION: 
      Immunoadsorption followed by IVIG administration further enhances LVEF, HF 
      symptoms, QoL and biomarkers in patients with recent-onset HF on OMT.
FAU - Weinmann, Karolina
AU  - Weinmann K
AD  - Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany. 
      Karolina.weinmann@uniklinik-ulm.de.
FAU - Werner, Jakob
AU  - Werner J
AD  - Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany. 
      jakob.werner@uni-ulm.de.
FAU - Koenig, Wolfgang
AU  - Koenig W
AD  - Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany. 
      Wolfgang.Koenig@uniklinik-ulm.de.
FAU - Rottbauer, Wolfgang
AU  - Rottbauer W
AD  - Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany. 
      Wolfgang.Rottbauer@uniklinik-ulm.de.
FAU - Walcher, Daniel
AU  - Walcher D
AD  - Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany. 
      Daniel.Walcher@uniklinik-ulm.de.
FAU - Kessler, Mirjam
AU  - Kessler M
AUID- ORCID: 0000-0001-6423-0508
AD  - Department of Internal Medicine II, University Hospital Ulm, 89081 Ulm, Germany. 
      mirjam.kessler@uniklinik-ulm.de.
LA  - eng
PT  - Journal Article
DEP - 20181102
PL  - Switzerland
TA  - Biomolecules
JT  - Biomolecules
JID - 101596414
RN  - 0 (Immunoglobulin G)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Adsorption
MH  - Adult
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/blood/diagnostic imaging/*physiopathology
MH  - *Heart Function Tests
MH  - Humans
MH  - Immunoglobulin G/blood
MH  - Immunoglobulins, Intravenous/administration & dosage/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/metabolism
MH  - Peptide Fragments/metabolism
MH  - Quality of Life
MH  - Surveys and Questionnaires
MH  - Ventricular Function, Left
PMC - PMC6315717
OTO - NOTNLM
OT  - cardiomyopathy
OT  - heart failure
OT  - immunoadsorption
OT  - responsiveness to therapy
COIS- The authors declare no conflict of interest.
EDAT- 2018/11/08 06:00
MHDA- 2019/06/14 06:00
PMCR- 2018/12/01
CRDT- 2018/11/08 06:00
PHST- 2018/09/04 00:00 [received]
PHST- 2018/10/17 00:00 [revised]
PHST- 2018/10/29 00:00 [accepted]
PHST- 2018/11/08 06:00 [entrez]
PHST- 2018/11/08 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/12/01 00:00 [pmc-release]
AID - biom8040133 [pii]
AID - biomolecules-08-00133 [pii]
AID - 10.3390/biom8040133 [doi]
PST - epublish
SO  - Biomolecules. 2018 Nov 2;8(4):133. doi: 10.3390/biom8040133.